The evolving need and challenges to reach LDL-C targets in high-risk patients

Kausik Ray, MD Imperical College London London, United Kingdom

The LDL-c challenge in high cardiovascular risk - Integrating innovative therapies in clinical management







Disclosures

- Research support from: Amgen, Sanofi, Regeneron, Daiichi Sankyo and Ultragenix
- Consulting fees from: Novartis, Daiichi Sankyo, Kowa, Esperion, Novo Nordisk, MSD, Lilly, Silence Therapeutics, AZ, New Amsterdam Pharma, Bayer, Beren Therapeutics, CLEERLY, EMENDOBIO, SCRIBE, CRISPR, VAXXINITY, Amarin, Regeneron, Ultragenix, Cargene, Resverlogix
- Speaker Honoraria from: Novartis, BI, AZ, Novo Nordisk, Viatris, Amarin, Biologix Pharma, Sanofi, Amgen, Esperion, Daiichi Sankyo, Macleod Pharma
- Options: New Amsterdam Pharma, PEMI31

RELEVANCE OF CHOLESTEROL TO CVD MORTALITY

Worldwide, there are more than 18 million deaths due to CVD each year






Tokgozoglu L EHJ 2022 doi.org /10.1093/Eurheartj/ehab841

Ray KK et al 2022 WHF Cholesterol Roadmap- Global Heart Journal DOI: https://doi.org/10.5334/gh.1154

Estimating benefit of initiating LDL-C lowering at different ages and by intensity early vs late in life




B. Moderate early LDL Lowering or more intense later LDL lowering

2022 WHF Cholesterol Roadmap- Global Heart DOI: https://doi.org/10.5334/gh.1154

Conceptual framework shift needed


- Start with risk assessment so you know how aggressively to treat
- Risk isn't dichotomous or qualitative (high / low etc) but a continuum
- We look at the past eg does clinical ASCVD exist reflects atherosclerosis burden over time missed year, and then factors that determine future progression – presence or absence of multiple additional risk factors and inherited vulnerability by considering family history

Treatment Goals for LDL-C Across Categories of Total Cardiovascular Disease Risk¹



1. Mach F et al. Eur Heart J. 2020;41:111-188.

2016–2019 ESC/EAS LDL-C Goals and Lipid Management in Clinical Practice



- ESC/EAS, European Society of Cardiology/European Atherosclerosis Society;
- EZE, ezetimibe; LDL-C, low-density lipoprotein cholesterol; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor
- 1. Catapano AL, et al. Eur Heart J. 2016;37:2999–3058; 2. Ray KK, et al. Eur J Prev Cardiol. 2021;28:1279–1289; 3. Mach F, et al. Eur Heart J. 2020;41:111–188; 3. 4. Ray KK, et al. Lancet Reg Health Eur. 2023;29:100624

Lipid-lowering Therapy Usage Across Countries

- Results from individual countries largely mirrored the trends observed overall
- Monotherapy was the most commonly used LLT across all patient subgroups regardless of the ASCVD status
- Countries with the highest rates of monotherapy (>70%) were:




• Countries with the highest rates of combination therapy (>30%) were:



ASCVD, atherosclerotic cardiovascular disease; **LDL-C**, low-density lipoprotein cholesterol; **LLT**, lipid-lowering therapy Ray KK, et al. Lancet Reg Health Eur. 2023;29:100624

LDL-C Goal Attainment by CV Risk, ASCVD Status and Lipid-lowering Therapy




LLT record was missing for patients n=1. Patients receiving monotherapy, n=1023/4902. Patients receiving combination therapy, n=2169. *Monotherapy including: statin alone; ezetimibe alone; PCSK9i alone; bempedoic acid alone; any other oral LLT alone; †Combination therapy including: statin + ezetimibe; PCSK9i combination; bempedoic acid fixed-dose combination; any other oral combination therapy; ‡Data are presented as mean ± SD

ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; EZE, ezetimibe; FDC, fixed-dose combination; HeFH, familial hypercholesterolaemia IQR, interquartile range; LDL-C, low-density lipoprotein; LLT, lipid-lowering therapy; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor; SD, standard deviation.

Ray KK, et al. Lancet Reg Health Eur. 2023;29:100624

12



Despite LDL-C levels above the recommended values, the majority of patients received monotherapy and 21.8% of patients had no documented LLT

Missing/not reported risk status, n=6 EZE, ezetimibe; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; PCSK9i, proprotein convertase subtilisin kexin 9 inhibitor

Ray KK, et al. Lancet Reg Health Eur. 2023;29:100624

Proportion of Patients at LDL-C Goal improved over 1 year with greater use of combination Tx and those not on LLT started


		Overall (N=7210)		High risk (N=2033)		Very high risk (N=5173)	
		Baseline	1-year follow-up	Baseline	1-year follow-up	Baseline	1-year follow-up
	LDL-C, mmol/L, mean (SD)	2.42 (1.22)	1.98 (0.95)	2.74 (1.31)	2.29 (1.03)	2.29 (1.15)	1.86 (0.88)
Ø	Patients at LDL-C goal, %	21.2	31.2	24.4	34.2	20.0	30.1

- Overall, LDL-C was reduced in both risk groups at follow-up versus baseline
- Among patients with available LDL-C data, more patients reached their LDL-C goals at follow-up versus baseline


LDL-C, low-density lipoprotein cholesterol; SD, standard deviation

Cholesterol control is fundamental in reducing the risk of ASCVD events^{1,2}


Lifetime exposure to elevated LDL-C is a causal and cumulative risk factor for ASCVD¹



 Sustained lifetime exposure to high cholesterol leads to an increase in the plaque burden and eventually to ASCVD events¹



World Heart Federation Cholesterol Road Map 2022



Conclusions



Underestimation of **CV risk** may lead to **undertreatment**



Greater combination therapy use is needed to reach Improve

LDL-C control

Doubling the dose of statin alone lowers LDL C by 6%, insufficient to achieve goals

• ESC/EAS, European Society of Cardiology/European Atherosclerosis Society; CV, cardiovascular; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy

• Ray KK, et al. Lancet Reg Health Eur. 2023;29:100624